Cutaneous malignant melanoma is a type of skin cancer. It starts in the cells that produce melanin, the pigment that gives your skin its color. Melanoma is the most dangerous type of skin cancer because it can spread to other parts of the body if not treated early. It often looks like a mole that has changed in size, shape, or color.
Every report comes from a Lived member, sent anonymously.
Have you tried Keytruda (Pembrolizumab) for Cutaneous Malignant Melanoma?
Cutaneous malignant melanoma is a cancer that starts in melanocytes, the skin cells that make pigment. It is far less common than other skin cancers, but more likely to grow deeper and spread to lymph nodes and other organs. That is why finding it early matters so much: melanoma caught while it is still confined to the skin is usually curable with surgery. Melanoma most often shows up as a new spot or an existing mole that changes in size, shape or color. A spot that looks different from a person's other moles (sometimes called the ugly duckling sign) is another warning. Doctors use the ABCDE features to describe suspicious spots: Asymmetry, an irregular Border, uneven Color, a Diameter usually larger than 6 millimeters (about the size of a pencil eraser, though melanomas can be smaller) and Evolving, meaning change over time. Melanoma can also itch, bleed or form a sore that does not heal. It can appear anywhere on the skin, including areas that rarely see the sun. In men it often appears on the trunk, head or neck; in women, on the arms and legs. Anyone can develop melanoma, including people with dark skin, in whom it more often appears on the palms, the soles or as a dark streak under a nail (acral melanoma). Melanoma of the eye or of the mucous membranes is a related but separate disease.
Melanoma begins when damage to the genes of a melanocyte lets it grow out of control. Ultraviolet (UV) light from the sun, tanning beds and sunlamps is the main cause of that damage for most melanomas. A history of blistering sunburns, especially in childhood or adolescence, raises risk. Other factors increase the likelihood without causing melanoma directly. These include fair skin that freckles or burns easily, light eyes, red or blond hair, having many moles or several large or unusual (atypical) moles, a personal or family history of melanoma, certain inherited gene changes and a weakened immune system, such as after an organ transplant. Unusual moles are a marker of higher risk, but most of them never become cancer, and most melanomas arise on skin without a preexisting atypical mole.
Diagnosis starts with a skin exam, often by a dermatologist, who looks closely at the suspicious spot and the rest of the skin. Because an early melanoma can be hard to tell apart from an ordinary mole, the only way to confirm it is a biopsy: removing all or part of the spot so a pathologist can examine it under a microscope. Removing the whole spot when practical gives the most complete information. Some people ask for a second pathologist to review the sample. The pathology report measures how deep the tumor reaches, in millimeters from the skin surface, and whether the skin over it has broken down (ulceration). Thickness and ulceration are central to staging. As a rough guide, stage I melanomas are no more than about 1 to 2 millimeters thick, while thicker or ulcerated tumors are stage II. Stage 0 (melanoma in situ) is confined to the top layer of skin. For tumors with a meaningful chance of spreading, a sentinel lymph node biopsy checks the first lymph node that drains the area. If melanoma has reached lymph nodes or nearby skin, it is stage III; spread to distant organs such as the lungs, liver, brain or bone is stage IV. Imaging scans (CT, PET or MRI) and a blood test for LDH (lactate dehydrogenase) are mainly used for more advanced disease. Melanoma that has spread is usually tested for gene changes, especially in BRAF, a gene that controls cell growth, because the result guides treatment.
Surgery is the main treatment at every stage. A wide local excision removes the melanoma with a margin of normal skin around it; occasionally a skin graft is needed to close the wound. For stage 0 and most stage I melanomas, this surgery is often the only treatment needed. If a sentinel lymph node contains only a small amount of cancer, regular ultrasound checks of the remaining nodes may be offered instead of removing them all. When the risk of the melanoma returning is high (some stage II and many stage III cases), medicine may be given after surgery, and sometimes before it, to lower that risk. The most widely used option is immunotherapy with checkpoint inhibitors such as pembrolizumab (Keytruda) and nivolumab (Opdivo), infusions that release a brake on the immune system so it can attack cancer cells. For melanomas with a change in the BRAF gene, found in about half of melanomas, a pill combination that blocks the overactive BRAF protein and a related growth signal called MEK, such as dabrafenib (Tafinlar) with trametinib (Mekinist), is an alternative. These drugs work only when the BRAF change is present. For melanoma that cannot be removed or has spread, immunotherapy (alone or in combinations) and BRAF/MEK targeted therapy are the main treatments. They can shrink tumors and control the disease for long periods in some people, though not everyone responds. Other options include a virus therapy injected directly into skin tumors, cell-based immunotherapy and radiation or surgery to relieve symptoms from tumors in places such as the brain or bone. Clinical trials are a common part of care for advanced melanoma. The trade-offs differ by family. Checkpoint inhibitors can make the immune system attack healthy organs, including the intestines, lungs, liver, skin and hormone-making glands. Most of these effects are mild and treatable if caught early, but some are serious and may require stopping treatment and taking medicines that calm the immune system. BRAF/MEK pills commonly cause fever, rash, tiredness and joint pain, and can lead to new, usually less serious skin cancers, so the skin is checked often during treatment.
The outlook depends mostly on how far melanoma has spread when it is found. In the United States, more than 99% of people whose melanoma is still confined to the skin are alive five years later, compared with similar people without melanoma. That figure is about 76% when it has reached nearby lymph nodes and 36% when it has spread to distant organs. These numbers come from people diagnosed several years ago, before some current treatments were widely used, and cannot predict any one person's course. After treatment, follow-up continues for years because melanoma can return and survivors have a higher chance of a new melanoma or another skin cancer. For early-stage melanoma that was fully removed, skin and lymph node exams are typically every 6 to 12 months for several years. Thicker or more advanced melanomas are usually checked every 3 to 6 months, sometimes with ultrasound or CT scans. Most doctors also recommend checking your own skin and lymph nodes at least monthly. Daily life often involves new sun habits: shade, protective clothing, broad-spectrum sunscreen and avoiding tanning beds. People on immunotherapy or targeted therapy may have treatment visits every few weeks and blood tests to watch for side effects. Some immune side effects, such as thyroid or other hormone problems, can last long after treatment ends and need ongoing care.
Have a doctor look at any new spot that seems unusual, a mole that is changing in size, shape or color, a spot that stands out from your others, a sore that bleeds or will not heal, or a new dark streak in a nail. If you have been treated for melanoma, contact your care team promptly about a new lump in the skin or near the scar, a swollen lymph node, or new symptoms such as persistent cough, shortness of breath, headaches, bone pain, abdominal swelling or loss of appetite, which can sometimes signal a return of the cancer. During immunotherapy, call your treatment team right away about new diarrhea or abdominal pain, a new cough or breathlessness, yellowing of the skin or eyes, a widespread rash, or unusual tiredness, headache or dizziness, since early treatment of immune side effects makes them easier to control.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Cutaneous Malignant Melanoma is like, what's helped you, or ask the community a question.